- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.11. | RECIPHARM AB: Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support | 1 | Cision News | ||
| 25.11. | Telomir reports PSA reduction in prostate cancer cells with lead drug | 2 | Investing.com | ||
| 25.11. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells | 224 | ACCESS Newswire | PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November... ► Artikel lesen | |
| 21.11. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells | 291 | ACCESS Newswire | Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL... ► Artikel lesen | |
| 20.11. | Craig Eagle verlässt Aufsichtsrat von Telomir Pharmaceuticals | 1 | Investing.com Deutsch | ||
| 20.11. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine in Reducing Intracellular Iron in a Human Cell Line | 299 | ACCESS Newswire | New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating... ► Artikel lesen | |
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.11. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11. | Telomir Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 23.10. | Telomir-1 shows promise in modulating cancer defense genes | 13 | Investing.com | ||
| 23.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's "Kill-and-Clean" Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo | 262 | ACCESS Newswire | New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ACCESS... ► Artikel lesen | |
| 22.10. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.10. | Telomir to Buy TELI | 2 | Baystreet.ca | ||
| 21.10. | Telomir Pharmaceuticals executes LOI for worldwide rights to Telomir-1 | 3 | Seeking Alpha | ||
| 21.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth | 282 | ACCESS Newswire | Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for partnerships, licensing, and long-term value creation.... ► Artikel lesen | |
| 14.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer | 195 | ACCESS Newswire | Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways. MIAMI... ► Artikel lesen | |
| 14.10. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 09.10. | Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug | 1 | Benzinga.com | ||
| 09.10. | Telomir stock soars after drug shows promise against aggressive breast cancer | 3 | Investing.com | ||
| 09.10. | Telomir-1 shows promise against triple-negative breast cancer | 4 | Investing.com |
1 2 3 4 Weiter >>
77 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,15 | +0,73 % | BioNTech: CureVac-Übernahme kurz vor Abschluss | Die BioNTech-Aktie wird aktuell bei 88 EUR gehandelt und gewinnt wieder an Dynamik. Während die Übernahme von CureVac in ihre finale Phase eintritt, sorgen gleichzeitig neue Forschungs-Updates und Analystenkommentare... ► Artikel lesen | |
| MODERNA | 21,910 | -0,57 % | Moderna, Lonza, NurExone: Wie Biotech-Akteure den Weg in neue Wachstumsfelder ebnen | ||
| VALNEVA | 3,788 | +0,26 % | Puma Aktie: Die Chance? - Bayer, Deutz, Rheinmetall, Smartbroker und Valneva im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,730 | -0,57 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| OCUGEN | 1,080 | +0,98 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,410 | +0,86 % | Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics | ||
| BAVARIAN NORDIC | 25,560 | -0,47 % | Bavarian Nordic A/S: Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million | COPENHAGEN, Denmark, December 2, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12... ► Artikel lesen | |
| GERON | 1,070 | -1,56 % | Geron Corporation Announces Executive Leadership Transitions and Appointments | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 1,973 | +0,05 % | ImmunityBio (IBRX) Slashes 9% on Lack of Leads | ||
| IOVANCE BIOTHERAPEUTICS | 1,879 | -0,32 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| ZAI LAB LTD ADR | 17,600 | +2,33 % | ZAI LAB (09688): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | ||
| VERASTEM | 8,900 | -2,20 % | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 19,010 | -0,23 % | Apellis' EMPAVELI shows 68% reduction in proteinuria for rare kidney diseases | ||
| ADMA BIOLOGICS | 20,110 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ANNOVIS BIO | 3,990 | -0,37 % | Annovis Bio Inc.: Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group |
TELOMIR PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,360 Euro und damit +3,03 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.